Why Pharmacyclics and J&J's Lack of Data Is So Amazing

Pharmacyclics and Johnson & Johnson's Imbruvica beat GlaxoSmithKline's Arzerra in a head-to-head trial. But by how much?

Jan 8, 2014 at 3:16PM

Way to go, Pharmacyclics (NASDAQ:PCYC) and Johnson & Johnson (NYSE:JNJ)! The companies said yesterday that they're ending a trial of their cancer drug Imbruvica early because of positive efficacy. 

It's not uncommon to see companies stopping clinical trials early after independent data monitoring committees conclude that the drug is working. At that point, it's unethical to continue the treatment in the inferior control arm.

What's remarkable about the latest trial that tested Imbruvica in patients with two different types of blood cancer is that patients taking the drug lived longer than those in the control arm.

When interim analyses are performed, they typically only show statistical significance in a surrogate endpoint called progression-free survival, a measurement of the time it takes for the disease to progress or for the patient to die, whichever comes first. Overall survival -- which just measures how long it takes for the patient to die -- may trend in the right direction, but it often doesn't reach statistical significance since most patients have measurable progression well before they die.

The Imbruvica trial analyzed progression-free survival -- it passed that measurement, too -- but the overall survival data is obviously much more important, because survival is what patients and their doctors care about.

Making the feat even more significant, Imbruvica beat GlaxoSmithKline's (NYSE:GSK) Arzerra, and the patients taking Arzerra were allowed to switch to Imbruvica once they progressed. That crossover won't affect the progression-free survival calculations, but for overall survival, Imbruvica was essentially competing against itself for some of the time patients were alive.

How good?
As is typical when companies stop clinical trials, Pharmacyclics and Johnson & Johnson didn't give any indication as to how much longer patients taking Imbruvica lived compared to those taking GlaxoSmithKline's Arzerra.

Companies like to withhold data to present at medical meetings, but when trials are stopped early, they can't even release top-line data, because there isn't time. It typically takes months to lock the database and do the statistical analysis, but companies don't have that kind of time when a clinical trial ends early. There are so many people involved in the trial that the ending of it would leak fairly quickly.

It's safe to assume, however, that Imbruvica extended survival substantially compared to Arzerra. To reach statistical significance, the difference would have to be fairly large given the low number of patients analyzed for the interim analysis.

Pharmacyclics and Johnson & Johnson would be best off releasing that data sooner rather than later. Imbruvica is already approved for the treatment of another blood cancer called mantle cell lymphoma, but doctors are allowed to prescribe drugs off-label for any disease they see fit. The companies could capture much of the late-stage chronic lymphocytic leukemia and small lymphocytic lymphoma markets before the FDA approves it for that indication if doctors knew how much better Imbruvica is than GlaxoSmithKline's Arzerra.

Our top pick in 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers